Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

RNXT

RenovoRx Inc

Apr 25 • 04:00PM ET

1.21

Dollar change -0.00
Percentage change -0.25	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	13.48%	Shs Outstand	16.87M	Perf Week	-0.82%
Market Cap	20.41M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.00%	Shs Float	14.59M	Perf Month	-6.92%
Income	-10.23M	PEG	-	EPS next Q	-0.13	Inst Own	1.96%	Short Float	0.45%	Perf Quarter	14.15%
Sales	0.00M	P/S	-	EPS this Y	55.00%	Inst Trans	1.73%	Short Ratio	1.34	Perf Half Y	9.99%
Book/sh	-0.28	P/B	-	EPS next Y	8.89%	ROA	-234.38%	Short Interest	0.07M	Perf Year	-55.84%
Cash/sh	0.07	P/C	17.45	EPS next 5Y	-	ROE	-646.98%	52W Range	0.53 - 3.29	Perf YTD	-47.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.39%	ROI	-	52W High	-63.22%	Beta	1.07
Dividend TTM	-	Quick Ratio	0.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	128.04%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	0.31	EPS Y/Y TTM	7.46%	Oper. Margin	0.00%	RSI (14)	45.17	Volatility	5.63% 10.91%
Employees	8	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.75
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-27.34%	Payout	-	Rel Volume	0.07	Prev Close	1.21
Sales Surprise	-	EPS Surprise	53.57%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	48.93K	Price	1.21
SMA20	-1.04%	SMA50	-13.05%	SMA200	-11.27%	Trades		Volume	3,465	Change	-0.25%

Apr-18-24 08:30AM	RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement (Business Wire)
Apr-16-24 08:30AM	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Apr-15-24 08:00AM	RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 (Business Wire) -5.74%
Apr-08-24 01:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023 (InvestorPlace)
08:30AM	RenovoRx Announces $11.1 Million at Market Private Placement (Business Wire)
08:30AM	Loading…
Apr-05-24 08:30AM	RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024 (Business Wire)
Mar-12-24 09:00AM	RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024 (Business Wire)
Mar-08-24 04:05PM	RenovoRx Highlights Key Leadership Promotions (Business Wire)
Feb-06-24 08:30AM	RenovoRx CEO Issues Letter to Shareholders (Business Wire)
Jan-29-24 08:30AM	RenovoRx Closes $6.1 Million Private Placement (Business Wire) +15.24%
Dec-21-23 08:30AM	RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer (Business Wire) +19.68%
Dec-19-23 08:30AM	RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting (Business Wire) -8.22%
Dec-13-23 08:31AM	RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform (Business Wire) +25.35%
Nov-16-23 08:35AM	RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D. (Business Wire) -15.82%
Nov-14-23 08:30AM	RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire) -28.34%
08:30AM	Loading…
Oct-02-23 08:30AM	RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023 (Business Wire) -16.92%
Aug-17-23 08:30AM	RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire) +7.60%
Jul-31-23 08:30AM	RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference (Business Wire)
Jul-20-23 08:00AM	RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform (Business Wire)
Jun-29-23 11:42AM	RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform (News Direct) +9.38%
08:00AM	RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer (Business Wire)
Jun-20-23 08:30AM	RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board (Business Wire)
Jun-12-23 08:30AM	RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15 (Business Wire)
Jun-01-23 08:30AM	RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire) +13.44%
May-25-23 08:30AM	RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer (Business Wire)
May-24-23 08:30AM	RenovoRx to Present at the LD Micro Invitational XIII Conference (Business Wire) -8.42%
May-15-23 08:30AM	RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire) +10.95%
May-01-23 08:30AM	RenovoRx Sponsors Pancreatic Cancer Action Networks PurpleStride® Event (Business Wire)
Apr-28-23 08:30AM	RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023 (Business Wire)
Apr-27-23 08:30AM	RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors (Business Wire) +11.87%
08:30AM	Loading…
Apr-14-23 08:30AM	RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida (Business Wire)
Apr-11-23 08:30AM	RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations (Business Wire)
Mar-30-23 12:20PM	RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (Business Wire) -13.59%
08:30AM	RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy (Business Wire)
Mar-22-23 09:00AM	RenovoRxs Principal Investigator of Phase III Clinical Trial Discusses Positive Interim Results on Patients with Locally Advanced Pancreatic Cancer on OncologyTube (News Direct)
Mar-08-23 12:26PM	RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care (Benzinga) +6.12%
08:30AM	RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer (Business Wire)
Mar-03-23 10:00AM	RenovoRX's Latest Innovative Technology Creates New Hope For Chemotherapy Patients (News Direct) +5.69%
Mar-02-23 08:30AM	RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone (Business Wire)
Mar-01-23 08:30AM	RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023 (Business Wire) +9.68%
Jan-25-23 08:30AM	RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023 (Business Wire)
Jan-18-23 12:31PM	RenovoRx Reports Initial Results From Targeted Treatment For Pancreatic Cancer (Benzinga) -7.59%
08:30AM	RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment (Business Wire)
Jan-11-23 10:43AM	Here's Why RenovoRx (NASDAQ:RNXT) Must Use Its Cash Wisely (Simply Wall St.) -5.68%
Jan-05-23 08:30AM	RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent (Business Wire)
Dec-15-22 08:30AM	RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium (Business Wire) +7.40%
Nov-17-22 08:30AM	RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers (Business Wire) -5.50%
Nov-14-22 08:30AM	RenovoRx Reports Third Quarter 2022 Financial Results (Business Wire)
Oct-21-22 08:30AM	RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET (Business Wire) -7.45%
Oct-04-22 08:00AM	RenovoRx to Participate in Upcoming October 2022 Investor Conferences (Business Wire)
Sep-28-22 08:30AM	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer (Business Wire) +8.11%
Sep-19-22 08:30AM	RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer (Business Wire)
Sep-07-22 08:00AM	RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022 (Business Wire) +6.49%
Aug-15-22 08:00AM	RenovoRx Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-04-22 10:48AM	Will RenovoRx (NASDAQ:RNXT) Spend Its Cash Wisely? (Simply Wall St.) -14.16%
Jul-19-22 08:30AM	RenovoRx Appoints James Ahlers as Chief Financial Officer (Business Wire)
Jul-13-22 08:00AM	RenovoRx Launches "The RenovoRx Story" Video Series (Business Wire)
Jun-09-22 08:30AM	RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP Webinar on June 21, 2022 (Business Wire)
Jun-02-22 08:30AM	RenovoRx to Participate in the University of Cambridges Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022 (Business Wire)
May-19-22 08:30AM	RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platforms Potential Utility for the Treatment of Bile Duct Cancer (Business Wire) -11.96%
May-18-22 08:00AM	RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022 (Business Wire) +14.21%
May-16-22 07:30AM	RenovoRx Reports First Quarter 2022 Financial Results (Business Wire)
Mar-30-22 08:30AM	RenovoRx Reports Full Year 2021 Financial Results (Business Wire)
Mar-11-22 08:30AM	RenovoRx to Participate in March 2022 Investor Conferences (Business Wire)
Feb-22-22 08:00AM	RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia Universitys New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial (Business Wire)
Feb-03-22 09:29AM	RenovoRx to Host "Delivering Therapy Where it Matters" Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET (Business Wire)
Jan-19-22 08:00AM	RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP Therapy for Targeted Treatment of Cancer (Business Wire)
Jan-06-22 08:00AM	RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference (Business Wire) -6.74%
Nov-26-21 06:28AM	We're Not Very Worried About RenovoRx's (NASDAQ:RNXT) Cash Burn Rate (Simply Wall St.)
Nov-15-21 04:15PM	RenovoRx Announces Third Quarter 2021 Financial Results (Business Wire)
Nov-11-21 06:00AM	RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting (Business Wire)
Nov-10-21 10:13AM	RNXT Stock Alert: 5 Things to Know as RenovoRx Soars 100%+ Today (InvestorPlace) +50.83%
09:44AM	RenovoRx Stock Soars 70% After Therapeutic Platform Presentation (Investing.com)
07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:52AM	30 Stocks Moving in Wednesday's Pre-Market Session (Benzinga)
Nov-09-21 06:00AM	Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer (Business Wire)
Sep-07-21 02:32PM	Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher (Benzinga) +26.11%
06:24AM	See Why RenovoRx Stock Is Shooting Higher On Tuesday (Benzinga)
06:00AM	RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors (PR Newswire)
Aug-30-21 12:15PM	35 Stocks Moving In Monday's Mid-Day Session (Benzinga) +107.78%
Aug-27-21 07:08AM	22 Stocks Moving in Friday's Pre-Market Session (Benzinga) +6.20%
Aug-15-21 11:05AM	The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow (Benzinga)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nelms Angela	Chief Operating Officer	Oct 03 '23	Buy	1.05	1,100	1,151	1,100	Oct 04 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNXT

RenovoRx Inc

Upgrade your FINVIZ experience